Key result
NLRP3 inflammasome inhibitor MCC950 did not alter Angiotensin II-induced hypertension (SBP 145±10 vs 139±7 mmHg), suggesting AT1R:AT2R expression drives the enhanced pressor response in aging.
Key points are not available for this paper at this time.
NLRP3 inhibition fails to blunt Ang II hypertension in aging; challenges inflammasome targeting and leaves open AT1R:AT2R modulation for study.
, Ang II-induced hypertension (SBP: 139±7 mmHg) was unaffected by co-infusion of the NLRP3 inflammasome inhibitor, MCC950 (10 mg/kg/d; SBP: 145±10 mmHg). Thus, increased vascular AT1R:AT2R expression, rather than NLRP3 inflammasome activation, may contribute to enhanced responses to Ang II in aging.
No takes yet. Share an insight, caveat, or question.
Dinh et al. (2017) studied this question. NLRP3 inflammasome inhibitor MCC950 did not alter Angiotensin II-induced hypertension (SBP 145±10 vs 139±7 mmHg), suggesting AT1R:AT2R expression drives the enhanced pressor response in aging.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: